Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study.
about
The relevance of beta-amyloid on markers of Alzheimer's disease in clinically normal individuals and factors that influence these associationsThe Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriersDevelopment of positron emission tomography β-amyloid plaque imaging agentsUshering in the study and treatment of preclinical Alzheimer diseaseImago Mundi, Imago AD, Imago ADNIPET amyloid-beta imaging in preclinical Alzheimer's diseaseAssociation of Longitudinal Cognitive Decline With Amyloid Burden in Middle-aged and Older Adults: Evidence for a Dose-Response Relationship.APOE ε4 genotype predicts memory for everyday activitiesSelf-reported confusion is related to global and regional β-amyloid: data from the Women's healthy ageing project.Cerebral Blood Flow and Amyloid-β Interact to Affect Memory Performance in Cognitively Normal Older Adults.Neuropathologic assessment of dementia markers in identical and fraternal twins.Development of a psychometrically equivalent short form of the Face-Name Associative Memory Exam for use along the early Alzheimer's disease trajectoryRelationship between memory performance and β-amyloid deposition at different stages of Alzheimer's disease.Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults.An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease.Molecular imaging of Alzheimer disease pathologyVascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly.Alzheimer disease biomarkers, attentional control, and semantic memory retrieval: Synergistic and mediational effects of biomarkers on a sensitive cognitive measure in non-demented older adults.Brain structure and function as mediators of the effects of amyloid on memory.Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort.Brain Amyloid Deposition and Longitudinal Cognitive Decline in Nondemented Older Subjects: Results from a Multi-Ethnic Population.Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's diseaseSelf-reported memory impairment and brain PET of amyloid and tau in middle-aged and older adults without dementiaCerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer diseaseEvidence for ordering of Alzheimer disease biomarkersSubjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies.Relationship between cerebrospinal fluid biomarkers of Alzheimer's disease and cognition in cognitively normal older adults.Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individualsVulnerable neural systems and the borderland of brain aging and neurodegenerationAn operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer diseaseShapes of the trajectories of 5 major biomarkers of Alzheimer diseaseMeta-analysis of amyloid-cognition relations in cognitively normal older adultsβ-Amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementiaAmyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease.Amyloid deposition, hypometabolism, and longitudinal cognitive declineMild cognitive impairment due to Alzheimer disease in the community.Cognitive aging in persons with minimal amyloid-β and white matter hyperintensities.Predicting episodic memory performance using different biomarkers: results from Argentina-Alzheimer's Disease Neuroimaging Initiative.The effect of amyloid β on cognitive decline is modulated by neural integrity in cognitively normal elderly.Assessing risk for preclinical β-amyloid pathology with APOE, cognitive, and demographic information.
P2860
Q26830467-2CA37036-FB56-4B2D-B11C-6F262ECE481CQ26849380-5A9F48E7-3426-4918-82EB-413717958584Q27012742-8993237C-6DCD-4ED3-9326-78FEBD30A9FCQ27014791-630C1FBC-BD73-4BC1-865C-9B861D0D503FQ28650395-D658BE5E-AB15-48C8-B7EA-EB2DAC35BB29Q30040695-D8120003-6584-443F-9D85-E061B3651019Q30101023-59AE0179-D18E-4E42-8509-25A7DD4686E0Q30661353-F4400A04-5590-44B8-8861-541BF02DF689Q31155701-91FDC304-153D-437A-B6A3-0B3A76839985Q33775095-0317EBB3-A909-4B6D-993F-AD41BA922F7EQ33784747-2423E5D7-13B2-47C3-895B-FE0C53F60695Q34051576-3FB118DA-AA8E-4291-AB2D-407CFE5BCF2DQ34149444-75309C22-FDF0-4DB2-8CD5-EBEE14C0E997Q34311853-F8180C87-65BB-438E-B886-4275F73D9126Q34364368-8D9A1E75-6B7C-451A-95D7-E58E64FCCBFDQ34651135-C9F230B3-957B-4437-94CA-315DE1DCD068Q35119419-045A6BC6-F77E-4862-A548-FAB51ECDF14EQ35185590-0C97A8AE-3E8C-43D8-A898-63D1DDF0B9CFQ35211063-DE39F6D1-98A5-448D-BE70-7CEE5ED0B2F1Q35342893-8D86A33C-6B1C-4A97-A85A-FC0786C565E8Q35722468-4266A3D2-657D-4C0A-96B9-64A3577911CAQ35776386-F2B3A096-B858-4F1E-A5D4-046B1B066101Q35953886-3AD6A427-DFCB-4984-AC24-FDA8202745DDQ36005633-E783CFBC-061D-4684-9077-2CB8CB650329Q36071403-D6D56039-A322-4251-B796-5EBE59962ADCQ36197614-A20109E6-0469-4F27-A70F-944B67C1AAE1Q36240571-2EC410A5-A546-4118-8816-91C9ACC2F844Q36457001-B14264AF-642B-4EF2-9D01-B2CB0D6C743CQ36573616-B4F988D1-6A59-4281-87F8-8AC77D589123Q36650399-A6888A3C-5398-4388-96AF-CF1DDE37C232Q36677361-45223B00-4079-414C-9C8B-BE413D0D5DCEQ36850873-ED36B15F-95CA-4258-AAD0-13D0DDA650DBQ36924335-5DA5B309-635D-4DBD-B05E-C7E78856329AQ37184248-71FBD768-9F8B-4B64-881D-A40FDBD9521AQ37207254-8E3949B1-E1D1-413E-8855-92D02E67324EQ37245465-CD6D433F-7C8C-4E31-9C71-46E506BECE2DQ37252248-2B4CDE4B-7D13-4753-975D-AFC10FB9FBBAQ37265898-43C71BBD-4C2C-48B9-B5C5-F07415D9E824Q37297360-6320E4F7-288E-4AA4-978B-D9909E3DD73AQ37303038-F8C972D1-A29E-4FCA-B7A4-BAA3313910DF
P2860
Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study.
@ast
Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study.
@en
type
label
Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study.
@ast
Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study.
@en
prefLabel
Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study.
@ast
Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study.
@en
P2093
P50
P1433
P1476
Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study.
@en
P2093
Christopher C Rowe
David Ames
Gael Chételat
Victor L Villemagne
P304
P356
10.1016/J.NEUROPSYCHOLOGIA.2011.04.012
P50
P577
2011-04-16T00:00:00Z